Feb 19, 2025 8:35am EST Sonnet BioTherapeutics Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform is Available for Drug Discovery Partnerships with Potential for Producing Multiple Pipeline Drug Candidates
Feb 18, 2025 9:15am EST Sonnet BioTherapeutics Selected for Poster Presentation at the 2025 AACR IO Conference
Feb 25, 2025 1:45 pm PST – 4:45 pm PST 2025 American Association for Cancer Research (AACR) IO Conference
